SCHEMBL26985159

SCHEMBL26985159

COc1cc2c(cc1C(N)=O)sc1nc(-c3ccc(C4CCN(C(=O)OC(C)(C)C)C4)cc3F)cn12

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 8/20 0.48
▸ GPR119 Q8TDV5 4/20 0.42
▸ JAK3 P52333 2/20 0.39
▸ LCK P06239 1/20 0.39
▸ BTK Q06187 1/20 0.39
▸ USP30 Q70CQ3 1/20 0.39
▸ JAK2 O60674 2/20 0.38
▸ PTK2 Q05397 1/20 0.38
▸ PDE4A P27815 1/20 0.38
▸ PDE4C Q08493 1/20 0.38
▸ PDE4D Q08499 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ ALOX5AP P20292 1/20 0.37
▸ FEN1 P39748 1/20 0.37
▸ ALK Q9UM73 1/20 0.37
▸ TRPV3 Q8NET8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30727304 1.00 PDE4B (0.48) PDE4BGPR119JAK3LCKBTK
SCHEMBL30727270 0.94 PDE4B (0.47) PDE4BGPR119JAK3LCKBTK
SCHEMBL31327730 0.94 PDE4B (0.47) PDE4BGPR119JAK3LCKBTK
SCHEMBL26985441 0.94 PDE4B (0.47) PDE4BGPR119JAK3LCKBTK
SCHEMBL30727293 0.93 PDE4B (0.46) PDE4BGPR119JAK3LCKBTK
SCHEMBL26985423 0.93 PDE4B (0.46) PDE4BGPR119JAK3LCKBTK
SCHEMBL31327740 0.92 PDE4B (0.45) PDE4BGPR119JAK3LCKBTK
SCHEMBL26985173 0.92 PDE4B (0.45) PDE4BGPR119JAK3LCKBTK
SCHEMBL30727281 0.92 PDE4B (0.45) PDE4BGPR119JAK3LCKBTK
SCHEMBL30727242 0.88 PDE4B (0.42) PDE4BJAK3LCKBTKUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-11-20 — — US disclosed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 — — WO disclosed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 PDE4B 3361/4885GPR119 4026/4885JAK3 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback